Treatment of Advanced Mucosal Melanoma with NRAS Mutation

This protocol applies to patients with advanced, unresectable, or metastatic mucosal melanoma in whom an NRAS gene mutation is confirmed. Molecular testing for NRAS status is central to treatment selection in this setting.

MEK inhibition shows acceptable tolerability and substantial clinical activity specifically in patients with NRAS-mutated melanoma, making NRAS mutation a key factor in directing therapy for advanced or metastatic disease.

The strategy centres on targeted therapy with a MEK inhibitor, addressing the NRAS-driven signalling pathway. The complete regimen, sequencing, and monitoring guidance are detailed in the full protocol.

Full agent selection, dosing, and decision algorithm are available in the structured protocol below.